Guo Shumeng, Wang Liangchun, Bu Dingfang, Liu Fengjie
Department of Dermatology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, China.
Department of Dermatology, Peking University First Hospital, Beijing, China.
World Allergy Organ J. 2024 Dec 11;18(1):101006. doi: 10.1016/j.waojou.2024.101006. eCollection 2025 Jan.
Dupilumab is the first monoclonal antibody approved for treating moderate-to-severe atopic dermatitis (AD) and has significantly improved the quality of life of AD patients. However, the safety of dupilumab is yet unclear in the context of cancer. Therefore, we aimed to investigate the safety of dupilumab and its relationship with the progression and occurrence of tumors. By reviewing relevant medical records of 90 patients who had pre-existing tumors before dupilumab treatment or presented new tumors after dupilumab treatment, we found that dupilumab probably had no significant negative effects on most tumors, but several patients with Cutaneous T-cell lymphomas (CTCLs) had relatively unfavorable outcomes during dupilumab treatment. Besides, CTCLs and lymphomas accounted for the majority of patients who presented new tumors after dupilumab treatment. Several patients were first diagnosed with presumed AD and probably were the presentations of CTCL at an early stage, and they developed typical CTCL symptoms after dupilumab treatment. Finally we came to the conclusion that dupilumab is safe for most patients with cancer. However, the effect of dupilumab on CTCLs is disputable. The use of dupilumab requires individual evaluation and closely monitored. When the efficacy is poor, re-evaluation of the diagnosis, especially of CTCLs and related diseases, is necessary.
度普利尤单抗是首个被批准用于治疗中度至重度特应性皮炎（AD）的单克隆抗体，显著改善了AD患者的生活质量。然而，在癌症背景下度普利尤单抗的安全性尚不清楚。因此，我们旨在研究度普利尤单抗的安全性及其与肿瘤进展和发生的关系。通过回顾90例在度普利尤单抗治疗前已有肿瘤或在度普利尤单抗治疗后出现新肿瘤患者的相关病历，我们发现度普利尤单抗可能对大多数肿瘤没有显著负面影响，但有几例皮肤T细胞淋巴瘤（CTCL）患者在度普利尤单抗治疗期间预后相对较差。此外，CTCL和淋巴瘤占度普利尤单抗治疗后出现新肿瘤患者的大多数。有几例患者最初被诊断为疑似AD，可能是早期CTCL的表现，在度普利尤单抗治疗后出现了典型的CTCL症状。最后我们得出结论，度普利尤单抗对大多数癌症患者是安全的。然而，度普利尤单抗对CTCL的影响存在争议。度普利尤单抗的使用需要个体化评估并密切监测。当疗效不佳时，有必要重新评估诊断，尤其是CTCL及相关疾病的诊断。
